Bladder Cancer Clinical Trial
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
Summary
Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
Eligibility Criteria
Inclusion Criteria:
You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body.
You must have at least one tumor that can be physically measured or scanned by x-ray.
You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago.
Exclusion Criteria:
You may not have used an experimental medicine or device within the past month.
Cancer that has spread to your brain.
If you are unwilling or unable to take folic acid or vitamin B12 supplements.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Los Angeles California, , United States
Palo Alto California, , United States
Boca Raton Florida, , United States
Tampa Florida, , United States
Decatur Illinois, , United States
Indianapolis Indiana, , United States
Lafayette Indiana, , United States
Muncie Indiana, , United States
South Bend Indiana, , United States
Lenexa Kansas, , United States
Saint Mathews Kentucky, , United States
Boston Massachusetts, , United States
Omaha Nebraska, , United States
Cleveland Ohio, , United States
Philadelphia Pennsylvania, , United States
Pittsburgh Pennsylvania, , United States
Nashville Tennessee, , United States
Fort Worth Texas, , United States
Houston Texas, , United States
Seattle Washington, , United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.